Expert Practice
Expert Practice
Expert Practice

prIME 3.0 New Event Page Layout

H2 lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna H2.

Not a member of My prIME? Join now for instant access.

Release Date

Release Date

Feb 23, 2018

Expiration Date

Feb 23, 2020

Date/Time

Date/Time

Downloadable Slides

Downloadable Slides

CME

CME

Downloadable Slides

Downloadable Slides

Location

Location

Meeting Overview-prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.H2lorem ipsum dolor sit amet, consectetur adipiscing elit, seddo eiusmod tempor incididunt ut labore et dolore magna H2.do eiusmod tempor incididunt ut labore et dolore magna H2.

Agenda

13.00 Welcome and introduction
Sibylle Loibl, MD, PhD
13.02 HER2+ early breast cancer: Clinical options
Sibylle Loibl, MD, PhD
13.05 HER2+ breast cancer: Remaining challenges after 20 years of trastuzumab
Suzette Delaloge, MD, MSc
13.20 Q & A
13.25 Adjuvant treatment for HER2+ breast cancer: When is trastuzumab not enough?
Wolfgang Janni, MD, PhD
13.40 Q & A
13.45 Metastatic HER2+ breast cancer: Clinical options
Sibylle Loibl, MD, PhD
13.50 Metastatic HER2+ breast cancer: The search for further treatment improvements
Pierfranco Conte, MD
14.05 Clinical case discussion
Sibylle Loibl, MD, PhD, and Faculty
14.13 prIME Points™
Sibylle Loibl, MD, PhD
14.15 Adjourn

    Faculty Title - 1

  • Elisabetta Abruzzese, MDSan Eugenio Hospital
    Rome, Italy
  • Sonia M. Abuzakhm, MDColumbus Oncology & Hematology Associates
    Columbus, Ohio, United States
  • Shaad Essa Abdullah, MDGreater Washington Oncology Associates
    Bethesda, Maryland
  • Matti Aapro, MDMultidisciplinary Oncology Institute
    Genolier, Switzerland
  • Ghassan Abou-Alfa, MD, MBAMemorial Sloan Kettering Cancer Center
    New York, New York, United States
  • Nadeem R. Abu-Rustum, MD, FACOG, FACSMemorial Sloan Kettering Cancer Center
    New York, New York, United States
  • Faculty Title - 2

  • Harvey Katzen, MDMaryland Oncology & Hematology
    Clinton, Maryland
  • Scott Kopetz, MD, PhD, FACPUniversity of Texas
    MD Anderson Cancer Center
    Houston, Texas, United States
  • Alan Kritz, MDREX Hematology Oncology Associates
    Raleigh, North Carolina, United States
  • Faculty for 2nd Meeting

  • Ghassan Abou-Alfa, MD, MBAMemorial Sloan Kettering Cancer Center
    New York, New York, United States
  • Nadeem R. Abu-Rustum, MD, FACOG, FACSMemorial Sloan Kettering Cancer Center
    New York, New York, United States
  • Sonia M. Abuzakhm, MDColumbus Oncology & Hematology Associates
    Columbus, Ohio, United States

*Additional faculty to be confirmed.

Target Audience-prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.H2lorem ipsum dolor sit amet, consectetur adipiscing elit, seddo eiusmod tempor incididunt ut labore et dolore magna H2.do eiusmod tempor incididunt ut labore et dolore magna H2.

Learning Objectives-prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.H2lorem ipsum dolor sit amet, consectetur adipiscing elit, seddo eiusmod tempor incididunt ut labore et dolore magna H2.do eiusmod tempor incididunt ut labore et dolore magna H2.

Support-prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.H2lorem ipsum dolor sit amet, consectetur adipiscing elit, seddo eiusmod tempor incididunt ut labore et dolore magna H2.do eiusmod tempor incididunt ut labore et dolore magna H2.

Continuing Education

Continuing Education-Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Provider

Provider H2 lorem ipsum dolor sit amet, consectetur adipiscing elit, seddo eiusmod tempor incididunt ut labore et dolore magna H2.

Important Disclosure

The information in this activity is intended for healthcare professionals based outside of the United States. You will be asked to provide your credentials before participating in the activity. This activity may contain information on products outside the approved indications where you practice.

Disclosures

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.